Baxter International (BAX) EBITDA (2009 - 2026)

Baxter International (BAX) has reported EBITDA for 18 consecutive years, with $217.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBITDA rose 13.61% year-over-year to $217.0 million in Q2 2026; TTM through Jun 2026 was $532.0 million, a 50.83% decrease from a year earlier, with the FY2025 full-year figure at -$308.0 million, down 2300.0% from the prior year.
• EBITDA was $217.0 million for Q2 2026 at Baxter International, up from $66.0 million in the prior quarter.
• Over five years, EBITDA peaked at $646.0 million in Q4 2023 and troughed at -$2.9 billion in Q3 2022.
• A 5-year average of -$103.0 million and a median of $129.0 million in 2023 frame the typical range for EBITDA.
• Across the five-year window, EBITDA slumped 1456.52% in 2022 and surged 307.05% in 2023, its largest moves.
• Over 5 years, EBITDA stood at -$312.0 million in 2022, then surged by 307.05% to $646.0 million in 2023, then slumped by 71.05% to $187.0 million in 2024, then gained by 2.14% to $191.0 million in 2025, then rose by 13.61% to $217.0 million in 2026.
• The last three EBITDA figures came in at $217.0 million (Q2 2026), $66.0 million (Q1 2026), and $191.0 million (Q2 2025), per Business Quant data.